Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
TARGET-NBL
Neuroblastoma
4 awards paid to create it · 15 awards funded work that used it
1. Awards that paid to create this data (4)
- Clinical Correlative Studies of Neuroblastoma · ROBERT Charles SEEGER · FY1998–2010
- The Genetic Basis of Neuroblastoma Tumorigenesis · JOHN M MARIS · FY2008–2017
- Children's Oncology Group Statistics and Data Center Grant · JAMES R ANDERSON, Meenakshi Devidas · FY2003–2013
- Children's Oncology Group Chair's Grant · PETER C. ADAMSON, GREGORY H REAMAN · FY2003–2013
2. The dataset
3. Articles that used it (6 of 8)
- Ma et al. · Nature · 2018797 citations
- Guo et al. · Nature communications · 2019236 citations
- Zimmerman et al. · Cancer discovery · 2018211 citations
- Zhu et al. · Cancer cell · 201781 citations
- Brohl et al. · Cell reports · 202166 citations
- Capasso et al. · Journal of cellular and molecular medicine · 201754 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 15)
- Children's Oncology Group Chair's Grant · PETER C. ADAMSON, GREGORY H REAMAN · FY2003–2013funded 1 of these 8 articles · also paid to create this data
- Cancer Biology (CBP) · Douglas R. Green, Elizabeth Fox · FY1985–2026funded 2 of these 8 articles
- Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resista… · Himisha Beltran, David S. Rickman · FY2017–2021funded 1 of these 8 articles
- Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer · A. THOMAS LOOK · FY2016–2022funded 1 of these 8 articles
- Antitumor Assessment · Elisa de Stanchina, FRANCESCA M GANY · FY1985–2026funded 2 of these 8 articles
- Role of LMO1 in Neuroblastoma Initiation and Maintenance · A. THOMAS LOOK, JOHN M MARIS · FY2015–2019funded 2 of these 8 articles
The best connected are shown.
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| R01CA060104 R01FY1998–2010$6.1M | Clinical Correlative Studies of Neuroblastoma | API |
| R01CA124709 R01FY2008–2017$6.3M | The Genetic Basis of Neuroblastoma Tumorigenesis | API2 |
| U10CA098413 U10FY2003–2013$67.5M | Children's Oncology Group Statistics and Data Center Grant | API |
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API2 |
Awards that funded work using this data
8 of 10 traced articles report an NCI award. 2 of these awards also paid to create the data - the same team publishing again on its own cohort, not a duplicated row.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API2 | |
| P30CA021765 P30FY1985–2026$336.2M | Cancer Biology (CBP) | API | |
| P50CA211024 P50FY2017–2021$21.8M | Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer | API | |
| R35CA210064 R35FY2016–2022$7.3M | Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer | API | |
| P30CA008748 P30FY1985–2026$717.9M | Antitumor Assessment | API | |
| R01CA180692 R01FY2015–2019$3.0M | Role of LMO1 in Neuroblastoma Initiation and Maintenance | API | |
| K08CA215105 K08FY2017–2021$854k | Precision Medicine by Targeting Cell Adhesion in Melanoma | API | |
| R00CA178189 R00FY2015–2017$747k | Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma | API | |
| R01CA104125 R01FY2004–2019$4.2M | Cytoskeletal Dynamics in Pancreatic Cancer Metastasis | API | |
| R01CA124709 R01FY2008–2017$6.3M | The Genetic Basis of Neuroblastoma Tumorigenesis | API2 | |
| R01CA196631 R01FY2016–2018$1.2M | A network platform to connect drug response and prognosis phenotypes for cancers | API | |
| P50CA217694 P50FY2018–2025$33.2M | Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma | API | |
| R01CA204974 R01FY2016–2020$1.9M | Structural Variation in Neuroblastoma | API | |
| R01CA237170 R01FY2019–2024$3.0M | Characterization of high-grade serous ovarian cancer subtypes via single-cell profiling | API | |
| R01CA236890 R01FY2020–2024$1.7M | Linking nucleotide and amino acid metabolism to cholesterol synthesis by MYCN | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P30CA008748 P30FY1985–2026$717.9M | Antitumor Assessment | API |
| P30CA021765 P30FY1985–2026$336.2M | Cancer Biology (CBP) | API |
| P50CA211024 P50FY2017–2021$21.8M | Project 1: Non-Invasive Clinical Assay for Early Detection of Treatment Resistance in Patients with Metastatic Prostate Cancer | API |
| P50CA217694 P50FY2018–2025$33.2M | Project 3: Identifying Targetable Epigenetic and Immuno-Oncologic Vulnerabilities in Synovial Sarcoma | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.